Moderna Stock Plummets as 2025 Sales Forecast Cut by $1 Billion Amid Vaccine Challenges
• 1 min read
Moderna's shares dropped 17% following a $1 billion reduction in its 2025 revenue forecast, driven by declining Covid vaccine market share and lower vaccination rates. The biotech company plans aggressive cost-cutting measures while maintaining optimism about its future product pipeline.
Johnson & Johnson Stock Dips Following Mixed Q1 Results and Revised 2024 Outlook
• 1 min read
Healthcare giant Johnson & Johnson experienced a 2% stock decline after reporting mixed Q1 2024 results, with revenue beating expectations but earnings falling short. The company narrowed its full-year guidance amid market uncertainties while maintaining its status as a dividend aristocrat.